Ikena Oncology Inc. (NASDAQ: IKNA) Stock Information | RedChip

Ikena Oncology Inc. (NASDAQ: IKNA) Listen to this Section


$1.71
+0.0250 ( +1.49% ) 99.6K

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Market Data


Open


$1.71

Previous close


$1.68

Volume


99.6K

Market cap


$82.52M

Day range


$1.68 - $1.73

52 week range


$1.02 - $5.21

Insider Ownership Transactions

Total Amount Purchased: -626,242.00 | $ -1,067,742.61

Date Type Amount Purchased Purchaser
2024-02-02 Sale -320000.00 Manfredi Mark
2023-09-14 Sale -153121.00 ORBIMED ADVISORS LLC
2023-09-14 Sale -153121.00 Bonita David P

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 36 May 28, 2024
10-q Quarterly Reports 55 May 13, 2024
ars Annual reports 1 Apr 26, 2024
def Proxies and info statements 5 Apr 26, 2024
10-k Annual reports 118 Mar 12, 2024
4 Insider transactions 1 Mar 05, 2024
3 Insider transactions 2 Mar 05, 2024
8-k 8K-related 17 Feb 21, 2024
4 Insider transactions 1 Feb 02, 2024
4 Insider transactions 1 Feb 02, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.